Sept. 19 /PRNewswire/ -- Oxford GlycoSciences (LSE: OGS) and Packard BioScience Company (Nasdaq: PBSC - news) announced today a collaboration to apply their respective technologies to develop protein biochips.
Commenting on the collaboration, Raj Parekh CSO of OGS said, ``We see microarrays for protein detection as the next major advance in analytical proteomics. The market potential of protein microarrays is very large with applications from basic research to clinical diagnostic tests. Packard have shown a real commitment to developing and expanding their micro-engineering and instrumentation technologies into the field of protein microarrays.''
Emery G. Olcott, President and CEO of Packard adds, ``We are pleased to collaborate with OGS, the leading company in proteomics, to take our biochip platform beyond genomics applications into the proteomics world. Our biochip platform technologies include proprietary ink-jet microarray printing robots, Hydrogel(TM) chip substrates and confocal laser scanners. We believe that this suite of fundamental tools will enable the manufacturing and use of protein microarrays. Such arrays are expected to become critical products to realize the goals of molecular medicine.''
OGS is the world's leading proteomics based drug discovery and development company headquartered in Oxfordshire, UK, applying its proteomics technology to pharmaceutical research and development. OGS has proteomics collaborations with a number of major pharmaceutical and biotechnology companies, including programs with Pfizer, Merck, Bayer, Pioneer Hi-Bred/DuPont, Medarex, Quintiles and Incyte Genomics. OGS has technology development collaborations with Cambridge Antibody Technology.
OGS has drug discovery programs in oncology, inflammation, and infectious disease, and a growing clinical and pre-clinical pipeline. Vevesca(TM) (formerly OGT 918) is in late stage clinical trials for the treatment of glycolipid storage disease.... |
